Zambia

Zambia

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
6.71 (5.36 - 7.99) 2019 Modelled IHME
6.72 (5.49 - 7.89) 2018 Modelled IHME
6.77 (5.58 - 7.93) 2017 Modelled IHME
7 (5.78 - 8.22) 2016 Modelled IHME
7.3 (5.95 - 8.66) 2015 Modelled IHME
7.5 (6.08 - 8.88) 2014 Modelled IHME
7.67 (6.21 - 9.09) 2013 Modelled IHME
7.83 (6.30 - 9.29) 2012 Modelled IHME
8 (6.44 - 9.50) 2011 Modelled IHME
8.22 (6.60 - 9.80) 2010 Modelled IHME
8.52 (6.81 - 10.19) 2009 Modelled IHME
8.92 (7.12 - 10.69) 2008 Modelled IHME
9.33 (7.44 - 11.20) 2007 Modelled IHME
9.7 (7.76 - 11.75) 2006 Modelled IHME
9.95 (7.89 - 12.14) 2005 Modelled IHME
10.11 (8.04 - 12.32) 2004 Modelled IHME
10.24 (8.09 - 12.56) 2003 Modelled IHME
10.35 (8.17 - 12.72) 2002 Modelled IHME
10.44 (8.23 - 12.85) 2001 Modelled IHME
10.54 (8.27 - 12.97) 2000 Modelled IHME
10.64 (8.43 - 13.02) 1999 Modelled IHME
10.74 (8.53 - 13.05) 1998 Modelled IHME
10.84 (8.66 - 13.08) 1997 Modelled IHME
10.93 (8.74 - 13.15) 1996 Modelled IHME
11 (8.75 - 13.22) 1995 Modelled IHME
11.06 (8.80 - 13.26) 1994 Modelled IHME
11.11 (8.84 - 13.30) 1993 Modelled IHME
11.16 (8.80 - 13.36) 1992 Modelled IHME
11.21 (8.76 - 13.55) 1991 Modelled IHME
11.25 (8.69 - 13.80) 1990 Modelled IHME
3.5 (3.30 - 3.80) 2016 Survey/reported Zambia Population-based HIV Impact Assessment (ZAMPHIA) 2016, 2019
4.06 (2.89 - 5.50) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.87 (0.62 - 1.15) 2019 Modelled IHME
0.91 (0.66 - 1.21) 2018 Modelled IHME
0.98 (0.72 - 1.31) 2017 Modelled IHME
1.12 (0.83 - 1.47) 2016 Modelled IHME
1.23 (0.88 - 1.61) 2015 Modelled IHME
1.23 (0.89 - 1.60) 2014 Modelled IHME
1.23 (0.89 - 1.59) 2013 Modelled IHME
1.23 (0.89 - 1.60) 2012 Modelled IHME
1.23 (0.89 - 1.61) 2011 Modelled IHME
1.23 (0.89 - 1.64) 2010 Modelled IHME
1.39 (1.02 - 1.85) 2009 Modelled IHME
1.8 (1.32 - 2.38) 2008 Modelled IHME
2.37 (1.74 - 3.11) 2007 Modelled IHME
3.02 (2.21 - 3.98) 2006 Modelled IHME
3.64 (2.64 - 4.84) 2005 Modelled IHME
4.37 (3.18 - 5.81) 2004 Modelled IHME
5.3 (3.83 - 7.06) 2003 Modelled IHME
6.22 (4.51 - 8.34) 2002 Modelled IHME
6.96 (5.03 - 9.34) 2001 Modelled IHME
7.33 (5.23 - 9.98) 2000 Modelled IHME
7.44 (5.37 - 9.97) 1999 Modelled IHME
7.53 (5.44 - 10.09) 1998 Modelled IHME
7.59 (5.45 - 10.18) 1997 Modelled IHME
7.64 (5.49 - 10.25) 1996 Modelled IHME
7.69 (5.52 - 10.30) 1995 Modelled IHME
7.73 (5.54 - 10.28) 1994 Modelled IHME
7.77 (5.56 - 10.27) 1993 Modelled IHME
7.81 (5.55 - 10.36) 1992 Modelled IHME
7.84 (5.52 - 10.42) 1991 Modelled IHME
7.86 (5.51 - 10.43) 1990 Modelled IHME
1.84 (1.17 - 2.76) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
30 (23 - 37) 2019 Modelled IHME
30 (23 - 38) 2018 Modelled IHME
30 (23 - 38) 2017 Modelled IHME
30 (23 - 38) 2016 Modelled IHME
30 (24 - 38) 2015 Modelled IHME
30 (24 - 38) 2014 Modelled IHME
30 (24 - 38) 2013 Modelled IHME
30 (24 - 38) 2012 Modelled IHME
30 (24 - 38) 2011 Modelled IHME
30 (24 - 39) 2010 Modelled IHME
30 (24 - 38) 2009 Modelled IHME
30 (24 - 38) 2008 Modelled IHME
30 (24 - 38) 2007 Modelled IHME
30 (24 - 38) 2006 Modelled IHME
30 (23 - 39) 2005 Modelled IHME
30 (23 - 39) 2004 Modelled IHME
30 (24 - 39) 2003 Modelled IHME
30 (24 - 39) 2002 Modelled IHME
30 (24 - 39) 2001 Modelled IHME
30 (23 - 40) 2000 Modelled IHME
30 (24 - 40) 1999 Modelled IHME
30 (24 - 39) 1998 Modelled IHME
30 (24 - 39) 1997 Modelled IHME
30 (23 - 39) 1996 Modelled IHME
30 (23 - 38) 1995 Modelled IHME
30 (23 - 38) 1994 Modelled IHME
29 (23 - 38) 1993 Modelled IHME
29 (22 - 37) 1992 Modelled IHME
29 (22 - 37) 1991 Modelled IHME
28 (21 - 36) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
90 2018 Survey/reported WHO/UNICEF
94 2017 Survey/reported WHO/UNICEF
91 2016 Survey/reported WHO/UNICEF
90 2015 Survey/reported WHO/UNICEF
86 2014 Survey/reported WHO/UNICEF
79 2013 Survey/reported WHO/UNICEF
78 2012 Survey/reported WHO/UNICEF
81 2011 Survey/reported WHO/UNICEF
83 2010 Survey/reported WHO/UNICEF
94 2009 Survey/reported WHO/UNICEF
87 2008 Survey/reported WHO/UNICEF
80 2007 Survey/reported WHO/UNICEF
81 2006 Survey/reported WHO/UNICEF
82 2005 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
0 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV elimination goal
HBV National Action Plan
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis treatment
Few (1-10%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
1.53 (1.22 - 1.91) 2019 Modelled IHME
1.53 (1.22 - 1.90) 2018 Modelled IHME
1.53 (1.22 - 1.91) 2017 Modelled IHME
1.53 (1.22 - 1.89) 2016 Modelled IHME
1.53 (1.22 - 1.89) 2015 Modelled IHME
1.53 (1.23 - 1.89) 2014 Modelled IHME
1.55 (1.24 - 1.90) 2013 Modelled IHME
1.56 (1.25 - 1.93) 2012 Modelled IHME
1.58 (1.26 - 1.97) 2011 Modelled IHME
1.59 (1.27 - 2) 2010 Modelled IHME
1.61 (1.29 - 2.02) 2009 Modelled IHME
1.63 (1.31 - 2.03) 2008 Modelled IHME
1.65 (1.32 - 2.06) 2007 Modelled IHME
1.67 (1.33 - 2.08) 2006 Modelled IHME
1.68 (1.35 - 2.09) 2005 Modelled IHME
1.7 (1.37 - 2.11) 2004 Modelled IHME
1.72 (1.38 - 2.14) 2003 Modelled IHME
1.73 (1.39 - 2.16) 2002 Modelled IHME
1.75 (1.40 - 2.19) 2001 Modelled IHME
1.76 (1.40 - 2.21) 2000 Modelled IHME
1.76 (1.41 - 2.21) 1999 Modelled IHME
1.77 (1.42 - 2.22) 1998 Modelled IHME
1.78 (1.42 - 2.22) 1997 Modelled IHME
1.78 (1.43 - 2.23) 1996 Modelled IHME
1.78 (1.42 - 2.22) 1995 Modelled IHME
1.79 (1.43 - 2.22) 1994 Modelled IHME
1.79 (1.43 - 2.23) 1993 Modelled IHME
1.79 (1.44 - 2.23) 1992 Modelled IHME
1.79 (1.43 - 2.24) 1991 Modelled IHME
1.79 (1.42 - 2.25) 1990 Modelled IHME
Showing out of
Show more

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
19 (14 - 26) 2019 Modelled IHME
19 (13 - 25) 2018 Modelled IHME
19 (13 - 25) 2017 Modelled IHME
19 (13 - 25) 2016 Modelled IHME
19 (13 - 25) 2015 Modelled IHME
19 (13 - 25) 2014 Modelled IHME
19 (13 - 25) 2013 Modelled IHME
18 (13 - 25) 2012 Modelled IHME
18 (13 - 24) 2011 Modelled IHME
18 (13 - 24) 2010 Modelled IHME
18 (12 - 24) 2009 Modelled IHME
18 (12 - 24) 2008 Modelled IHME
18 (12 - 24) 2007 Modelled IHME
18 (12 - 24) 2006 Modelled IHME
18 (12 - 24) 2005 Modelled IHME
18 (12 - 24) 2004 Modelled IHME
18 (12 - 24) 2003 Modelled IHME
18 (12 - 24) 2002 Modelled IHME
18 (12 - 24) 2001 Modelled IHME
18 (12 - 24) 2000 Modelled IHME
18 (12 - 24) 1999 Modelled IHME
18 (12 - 24) 1998 Modelled IHME
18 (12 - 24) 1997 Modelled IHME
18 (12 - 24) 1996 Modelled IHME
18 (12 - 24) 1995 Modelled IHME
18 (12 - 24) 1994 Modelled IHME
18 (12 - 24) 1993 Modelled IHME
18 (12 - 24) 1992 Modelled IHME
18 (13 - 24) 1991 Modelled IHME
18 (13 - 24) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV elimination goal
HBV National Action Plan
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis treatment
Few (1-10%)

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
6.71 (%)
2019
(5.36 - 7.99(%))
IHME
HCV (RNA/cAg+)
1.53 (%)
2019
(1.22 - 1.91(%))
IHME

Survey/surveillance

HBV (HBsAg+)
3.5 (%)
2016
(3.3 - 3.8(%))
Zambia Population-based HIV Impact Assessment (ZAMPHIA) 2016, 2019
No data available

Hepatitis related deaths (national)

Modelled

HBV
868
2019
(600 - 1,223)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
1,730
2019
(1,221 - 2,357)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.87 (%)
2019, latest modelled
(0.62 - 1.15(%))
IHME

Prevalence PWID

No data available

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

HCV
0
2016
(0 - 0)
Harm Reduction International, 2016
Eligible for HBV generic medicines
Eligible for HCV generic medicines